People · Operator
Named in public records as an officer, director or promoter · active 2010–2017 · Biotechnology, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| O2 Medtech Inc | — | Biotechnology | Seed | $7.1M | $160.3M | 2010 |
| Qview Medical, Inc. | — | Healthtech | Series A | $6.8M | $45.1M | 2013 |
| Endosee Corp | — | Biotechnology | Seed | $5.4M | $80.2M | 2011 |
| UroSee Corp | — | Other Health Care | Pre-Seed | $500K | $15.4M | 2017 |
Shih-Ping (Bob) Wang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shih-Ping (Bob) Wang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Xiaolong (Bruce) OuYang | 2 | 2 |
| John Pavlidis | 1 | 4 |
| Wayne Wu | 1 | 4 |
| Wei Zhang | 1 | 3 |
| Gordon Hull | 1 | 2 |
| Kevin Rooney | 1 | 2 |
| Paul D. Indman | 1 | 1 |
| Ron K. Ho | 1 | 1 |
| Kevin D. Rooney | 1 | 1 |
| Zengpin Yu | 1 | 1 |
| Paul Chan | 1 | 1 |
| Kevin K. Rooney | 1 | 1 |
| Nico Karssemeijer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.